Now showing items 568-587 of 1090

    • Magnetic resonance imaging (MRI) guided radiotherapy for prostate cancer 

      Pathmanathan, A (2020-11-30)
      Radiotherapy to the prostate involves increasingly sophisticated delivery techniques and changing fractionation schedules. Magnetic resonance imaging (MRI) guided radiotherapy allows daily adaptive replanning and can improve ...
    • Magnetic resonance imaging in precision radiation therapy for lung cancer. 

      Bainbridge, H; Salem, A; Tijssen, RHN; Dubec, M; Wetscherek, A; Van Es, C; Belderbos, J; Faivre-Finn, C; McDonald, F; lung tumour site group of the international Atlantic MR-Linac Consortium (2017-12)
      Radiotherapy remains the cornerstone of curative treatment for inoperable locally advanced lung cancer, given concomitantly with platinum-based chemotherapy. With poor overall survival, research efforts continue to explore ...
    • Magnetic resonance imaging sequence evaluation of an MR Linac system; early clinical experience. 

      Eccles, CL; Adair Smith, G; Bower, L; Hafeez, S; Herbert, T; Hunt, A; McNair, HA; Ofuya, M; Oelfke, U; Nill, S; Huddart, RA; PRIMER TMG (2019-12-16)
      Objectives:To systematically identify the preferred magnetic resonance imaging (MRI) sequences following volunteer imaging on a 1.5 Tesla (T) MR-Linear Accelerator (MR Linac) for future protocol development. Methods:Non-patient ...
    • Magnetic Resonance Imaging-Based Assessment of Breast Cancer-Related Lymphoedema Tissue Composition. 

      Borri, M; Gordon, KD; Hughes, JC; Scurr, ED; Koh, D-M; Leach, MO; Mortimer, PS; Schmidt, MA (2017-09)
      Objectives The aim of this study was to propose a magnetic resonance imaging acquisition and analysis protocol that uses image segmentation to measure and depict fluid, fat, and muscle volumes in breast cancer-related ...
    • Magnetic Resonance Imaging-Guided Adaptive Radiation Therapy: A "Game Changer" for Prostate Treatment? 

      Pathmanathan, AU; van As, NJ; Kerkmeijer, LGW; Christodouleas, J; Lawton, CAF; Vesprini, D; van der Heide, UA; Frank, SJ; Nill, S; Oelfke, U; van Herk, M; Li, XA; Mittauer, K; Ritter, M; Choudhury, A; Tree, AC (2018-02)
      Radiation therapy to the prostate involves increasingly sophisticated delivery techniques and changing fractionation schedules. With a low estimated α/β ratio, a larger dose per fraction would be beneficial, with moderate ...
    • Magnetic Resonance Spectroscopy to Study Glycolytic Metabolism During Autophagy. 

      Chung, Y-L; Leach, MO; Eykyn, TR (2017-01)
      Cancer cells undergoing starvation- and treatment-induced autophagy were found to exhibit reduced intracellular lactate, reduced rates of steady-state lactate excretion and reduced real-time pyruvate-lactate exchange rates, ...
    • Magnetic Resonance-based Response Assessment and Dose Adaptation in Human Papilloma Virus Positive Tumors of the Oropharynx treated with Radiotherapy (MR-ADAPTOR): An R-IDEAL stage 2a-2b/Bayesian phase II trial. 

      Bahig, H; Yuan, Y; Mohamed, ASR; Brock, KK; Ng, SP; Wang, J; Ding, Y; Hutcheson, K; McCulloch, M; Balter, PA; Lai, SY; Al-Mamgani, A; Sonke, J-J; van der Heide, UA; Nutting, C; Li, XA; Robbins, J; Awan, M; Karam, I; Newbold, K; Harrington, K; Oelfke, U; Bhide, S; Philippens, MEP; Terhaard, CHJ; McPartlin, AJ; Blanchard, P; Garden, AS; Rosenthal, DI; Gunn, GB; Phan, J; Cazoulat, G; Aristophanous, M; McSpadden, KK; Garcia, JA; van den Berg, CAT; Raaijmakers, CPJ; Kerkmeijer, L; Doornaert, P; Blinde, S; Frank, SJ; Fuller, CD (2018-11)
      Background Current standard radiotherapy for oropharynx cancer (OPC) is associated with high rates of severe toxicities, shown to adversely impact patients' quality of life. Given excellent outcomes of human papilloma virus ...
    • Magnitude of observer error using cone beam CT for prostate interfraction motion estimation: effect of reducing scan length or increasing exposure. 

      McNair, HA; Harris, EJ; Hansen, VN; Thomas, K; South, C; Hafeez, S; Huddart, R; Dearnaley, DP (2015-10)
      Objective Cone beam CT (CBCT) enables soft-tissue registration to planning CT for position verification in radiotherapy. The aim of this study was to determine the interobserver error (IOE) in prostate position verification ...
    • Major Amputations for Extremity Soft-Tissue Sarcoma. 

      Smith, HG; Thomas, JM; Smith, MJF; Hayes, AJ; Strauss, DC (2018-02)
      Introduction With modern techniques facilitating limb conservation, amputation for extremity soft-tissue sarcoma (ESTS) is now rare. We sought to determine the indications and outcomes following major amputation for ESTS ...
    • Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. 

      Silvestri, V; Barrowdale, D; Mulligan, AM; Neuhausen, SL; Fox, S; Karlan, BY; Mitchell, G; James, P; Thull, DL; Zorn, KK; Carter, NJ; Nathanson, KL; Domchek, SM; Rebbeck, TR; Ramus, SJ; Nussbaum, RL; Olopade, OI; Rantala, J; Yoon, S-Y; Caligo, MA; Spugnesi, L; Bojesen, A; Pedersen, IS; Thomassen, M; Jensen, UB; Toland, AE; Senter, L; Andrulis, IL; Glendon, G; Hulick, PJ; Imyanitov, EN; Greene, MH; Mai, PL; Singer, CF; Rappaport-Fuerhauser, C; Kramer, G; Vijai, J; Offit, K; Robson, M; Lincoln, A; Jacobs, L; Machackova, E; Foretova, L; Navratilova, M; Vasickova, P; Couch, FJ; Hallberg, E; Ruddy, KJ; Sharma, P; Kim, S-W; kConFab Investigators; Teixeira, MR; Pinto, P; Montagna, M; Matricardi, L; Arason, A; Johannsson, OT; Barkardottir, RB; Jakubowska, A; Lubinski, J; Izquierdo, A; Pujana, MA; Balmaña, J; Diez, O; Ivady, G; Papp, J; Olah, E; Kwong, A; Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON); Nevanlinna, H; Aittomäki, K; Perez Segura, P; Caldes, T; Van Maerken, T; Poppe, B; Claes, KBM; Isaacs, C; Elan, C; Lasset, C; Stoppa-Lyonnet, D; Barjhoux, L; Belotti, M; Meindl, A; Gehrig, A; Sutter, C; Engel, C; Niederacher, D; Steinemann, D; Hahnen, E; Kast, K; Arnold, N; Varon-Mateeva, R; Wand, D; Godwin, AK; Evans, DG; Frost, D; Perkins, J; Adlard, J; Izatt, L; Platte, R; Eeles, R; Ellis, S; EMBRACE; Hamann, U; Garber, J; Fostira, F; Fountzilas, G; Pasini, B; Giannini, G; Rizzolo, P; Russo, A; Cortesi, L; Papi, L; Varesco, L; Palli, D; Zanna, I; Savarese, A; Radice, P; Manoukian, S; Peissel, B; Barile, M; Bonanni, B; Viel, A; Pensotti, V; Tommasi, S; Peterlongo, P; Weitzel, JN; Osorio, A; Benitez, J; McGuffog, L; Healey, S; Gerdes, A-M; Ejlertsen, B; Hansen, TVO; Steele, L; Ding, YC; Tung, N; Janavicius, R; Goldgar, DE; Buys, SS; Daly, MB; Bane, A; Terry, MB; John, EM; Southey, M; Easton, DF; Chenevix-Trench, G; Antoniou, AC; Ottini, L (2016-02-09)
      Background BRCA1 and, more commonly, BRCA2 mutations are associated with increased risk of male breast cancer (MBC). However, only a paucity of data exists on the pathology of breast cancers (BCs) in men with BRCA1/2 ...
    • Management of localized seminoma, stage I-II: SIU/ICUD Consensus Meeting on Germ Cell Tumors (GCT), Shanghai 2009. 

      Warde, P; Huddart, R; Bolton, D; Heidenreich, A; Gilligan, T; Fossa, S (2011-10)
      The treatment of patients with Stage I-II seminoma has changed considerably in the past decade, and in November 2009, an International Consensus meeting was held under the sponsorship of the Union for International Cancer ...
    • Management of Men with Prostate-specific Antigen Failure After Prostate Radiotherapy: The Case Against Early Androgen Deprivation. 

      Brand, D; Parker, C (2018-04)
      In men with prostate-specific antigen failure after radical radiotherapy, androgen deprivation therapy should be delayed until the site of recurrence is known to allow consideration of curative treatment options, to delay ...
    • Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. 

      Gillessen, S; Omlin, A; Attard, G; de Bono, JS; Efstathiou, E; Fizazi, K; Halabi, S; Nelson, PS; Sartor, O; Smith, MR; Soule, HR; Akaza, H; Beer, TM; Beltran, H; Chinnaiyan, AM; Daugaard, G; Davis, ID; De Santis, M; Drake, CG; Eeles, RA; Fanti, S; Gleave, ME; Heidenreich, A; Hussain, M; James, ND; Lecouvet, FE; Logothetis, CJ; Mastris, K; Nilsson, S; Oh, WK; Olmos, D; Padhani, AR; Parker, C; Rubin, MA; Schalken, JA; Scher, HI; Sella, A; Shore, ND; Small, EJ; Sternberg, CN; Suzuki, H; Sweeney, CJ; Tannock, IF; Tombal, B (2019-12)
    • Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. 

      Gillessen, S; Attard, G; Beer, TM; Beltran, H; Bjartell, A; Bossi, A; Briganti, A; Bristow, RG; Chi, KN; Clarke, N; Davis, ID; de Bono, J; Drake, CG; Duran, I; Eeles, R; Efstathiou, E; Evans, CP; Fanti, S; Feng, FY; Fizazi, K; Frydenberg, M; Gleave, M; Halabi, S; Heidenreich, A; Heinrich, D; Higano, CTS; Hofman, MS; Hussain, M; James, N; Kanesvaran, R; Kantoff, P; Khauli, RB; Leibowitz, R; Logothetis, C; Maluf, F; Millman, R; Morgans, AK; Morris, MJ; Mottet, N; Mrabti, H; Murphy, DG; Murthy, V; Oh, WK; Ost, P; O'Sullivan, JM; Padhani, AR; Parker, C; Poon, DMC; Pritchard, CC; Reiter, RE; Roach, M; Rubin, M; Ryan, CJ; Saad, F; Sade, JP; Sartor, O; Scher, HI; Shore, N; Small, E; Smith, M; Soule, H; Sternberg, CN; Steuber, T; Suzuki, H; Sweeney, C; Sydes, MR; Taplin, M-E; Tombal, B; Türkeri, L; van Oort, I; Zapatero, A; Omlin, A (2020-04)
      Background Innovations in treatments, imaging, and molecular characterisation in advanced prostate cancer have improved outcomes, but there are still many aspects of management that lack high-level evidence to inform ...
    • Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. 

      Gillessen, S; Attard, G; Beer, TM; Beltran, H; Bossi, A; Bristow, R; Carver, B; Castellano, D; Chung, BH; Clarke, N; Daugaard, G; Davis, ID; de Bono, J; Borges Dos Reis, R; Drake, CG; Eeles, R; Efstathiou, E; Evans, CP; Fanti, S; Feng, F; Fizazi, K; Frydenberg, M; Gleave, M; Halabi, S; Heidenreich, A; Higano, CS; James, N; Kantoff, P; Kellokumpu-Lehtinen, P-L; Khauli, RB; Kramer, G; Logothetis, C; Maluf, F; Morgans, AK; Morris, MJ; Mottet, N; Murthy, V; Oh, W; Ost, P; Padhani, AR; Parker, C; Pritchard, CC; Roach, M; Rubin, MA; Ryan, C; Saad, F; Sartor, O; Scher, H; Sella, A; Shore, N; Smith, M; Soule, H; Sternberg, CN; Suzuki, H; Sweeney, C; Sydes, MR; Tannock, I; Tombal, B; Valdagni, R; Wiegel, T; Omlin, A (2018-02)
      Background In advanced prostate cancer (APC), successful drug development as well as advances in imaging and molecular characterisation have resulted in multiple areas where there is lack of evidence or low level of evidence. ...
    • Managing adverse events associated with vismodegib in the treatment of basal cell carcinoma. 

      Fife, K; Herd, R; Lalondrelle, S; Plummer, R; Strong, A; Jones, S; Lear, JT (2017-01)
      Basal cell carcinomas are the most common form of skin cancer. Some develop into advanced cases not suitable for standard therapy. Vismodegib is the first-in-class oral hedgehog pathway inhibitor (which is dysregulated in ...
    • Managing Nonmetastatic Castration-resistant Prostate Cancer. 

      Mateo, J; Fizazi, K; Gillessen, S; Heidenreich, A; Perez-Lopez, R; Oyen, WJG; Shore, N; Smith, M; Sweeney, C; Tombal, B; Tomlins, SA; de Bono, JS (2019-02)
      CONTEXT:Patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) have rising prostate-specific antigen (PSA) and castrate testosterone levels, with no radiological findings of metastatic disease on computed ...
    • Mapping Hypoxia in Renal Carcinoma with Oxygen-enhanced MRI: Comparison with Intrinsic Susceptibility MRI and Pathology. 

      Little, RA; Jamin, Y; Boult, JKR; Naish, JH; Watson, Y; Cheung, S; Holliday, KF; Lu, H; McHugh, DJ; Irlam, J; West, CML; Betts, GN; Ashton, G; Reynolds, AR; Maddineni, S; Clarke, NW; Parker, GJM; Waterton, JC; Robinson, SP; O'Connor, JPB (2018-09)
      Purpose To cross-validate T1-weighted oxygen-enhanced (OE) MRI measurements of tumor hypoxia with intrinsic susceptibility MRI measurements and to demonstrate the feasibility of translation of the technique for patients. ...
    • Marital status and prostate cancer incidence: a pooled analysis of 12 case-control studies from the PRACTICAL consortium. 

      Salmon, C; Song, L; Muir, K; UKGPCS Collaborators; Pashayan, N; Dunning, AM; Batra, J; APCB BioResource (Australian Prostate Cancer BioResource); Chambers, S; Stanford, JL; Ostrander, EA; Park, JY; Lin, H-Y; Cussenot, O; Cancel-Tassin, G; Menegaux, F; Cordina-Duverger, E; Kogevinas, M; Llorca, J; Kaneva, R; Slavov, C; Razack, A; Lim, J; Gago-Dominguez, M; Castelao, JE; Kote-Jarai, Z; Eeles, RA; on behalf of the PRACTICAL Consortium; Parent, M-É (2021-07-18)
      While being in a committed relationship is associated with a better prostate cancer prognosis, little is known about how marital status relates to its incidence. Social support provided by marriage/relationship could promote ...